Research ArticleCancer

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers

See allHide authors and affiliations

Science Translational Medicine  19 Feb 2020:
Vol. 12, Issue 531, eaax2625
DOI: 10.1126/scitranslmed.aax2625

Article Information

vol. 12 no. 531

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication March 12, 2019
  • Resubmitted October 17, 2019
  • Accepted for publication January 16, 2020
  • .

Author Information

  1. Florence Coussy1,2,3,
  2. Rania El-Botty1,
  3. Sophie Château-Joubert4,
  4. Ahmed Dahmani1,
  5. Elodie Montaudon1,
  6. Sophie Leboucher5,
  7. Ludivine Morisset1,
  8. Pierre Painsec1,
  9. Laura Sourd1,
  10. Léa Huguet1,
  11. Fariba Nemati1,
  12. Jean-Luc Servely4,6,
  13. Thibaut Larcher7,
  14. Sophie Vacher3,
  15. Adrien Briaux3,
  16. Cécile Reyes1,
  17. Philippe La Rosa8,9,
  18. Georges Lucotte8,9,
  19. Tatiana Popova9,10,
  20. Pierre Foidart11,
  21. Nor Eddine Sounni11,
  22. Agnès Noel11,
  23. Didier Decaudin1,2,
  24. Laetitia Fuhrmann12,
  25. Anne Salomon12,
  26. Fabien Reyal13,14,
  27. Christopher Mueller15,
  28. Petra Ter Brugge16,
  29. Jos Jonkers16,
  30. Marie-France Poupon1,
  31. Marc-Henri Stern9,10,
  32. Ivan Bièche3,
  33. Yves Pommier17,* and
  34. Elisabetta Marangoni1,*
  1. 1Translational Research Department, Institut Curie, PSL Research University, 75005 Paris, France.
  2. 2Medical Oncology Department, Institut Curie, PSL Research University, 75005 Paris, France.
  3. 3Genetics Department, Institut Curie, PSL Research University, 75005 Paris, France.
  4. 4BioPôle Alfort, Ecole Nationale Vétérinaire d'Alfort, 94704 Maisons Alfort, France.
  5. 5Institut Curie, PSL Research University, UMR3306, 91405 Orsay, France.
  6. 6INRA, PHASE Department, 37380 Nouzilly, France.
  7. 7INRA, APEX-PAnTher, Oniris, 44300 Nantes, France.
  8. 8INSERM, U900, 75005 Paris, France.
  9. 9Institut Curie, PSL Research University, 75005 Paris, France.
  10. 10INSERM U830, 75005 Paris, France.
  11. 11Laboratory of Tumor and Developmental Biology, Groupe Interdisciplinaire de Génoprotéomique Appliqué-Cancer (GIGA-Cancer), University of Liège, Liège 4000, Belgium.
  12. 12Department of Pathology, Institut Curie, PSL Research University, 75005 Paris, France.
  13. 13Surgery Department, Institut Curie, PSL Research University, 75005 Paris, France.
  14. 14U932, Immunity and Cancer, INSERM, Institut Curie, 75005 Paris, France.
  15. 15Queen's Cancer Research Institute, Queen's University, Kingston, ON K7L 3N6, Canada.
  16. 16Division of Molecular Pathology and Cancer Genomics Centre Netherlands, Netherlands Cancer Institute, Amsterdam, 1066 CX, Netherlands.
  17. 17Developmental Therapeutics Branch and Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
  1. *Corresponding author. Email: elisabetta.marangoni{at}curie.fr (E.M.); pommier{at}nih.gov (Y.P.)

Altmetric

Article usage

Article usage: February 2020 to November 2020

AbstractFullPdf
Feb 20204226569326
Mar 2020523146151
Apr 20202017759
May 20202154049
Jun 20201404159
Jul 20201394630
Aug 2020983734
Sep 20201536236
Oct 20201734440
Nov 20201173742

Stay Connected to Science Translational Medicine